Sight Sciences (SGHT) AI Stock Analysis

• Market Cap: $260.79M
• Dividend Yield: N/A
• Average Volume (3M): 150.61K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.84
• Revenue Growth: -3.89%
• EPS Growth: 9.68%
• Country: US
• Employees: 216
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.16
• Shares Outstanding: 52,367,360
• 10 Day Avg. Volume: 244,568
• 30 Day Avg. Volume: 150,613
• PEG Ratio: 0.37
• Price to Book (P/B): 2.09
• Price to Sales (P/S): 2.28
• P/FCF Ratio: -8.03
• Enterprise Value/Market Cap: 0.59
• Enterprise Value/Revenue: 2.01
• Enterprise Value/Gross Profit: 2.34
• Enterprise Value/Ebitda: -3.58
• 1Y Price Target: $4.83
• Price Target Upside: -17.01% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 7
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 58 Neutral
• Price Target: $5.00 ▼(-14.09% Downside)

The overall stock score is primarily influenced by strong technical momentum and a solid liquidity position. However, financial performance challenges, including declining revenues and net losses, weigh heavily. Mixed sentiment from the earnings call and valuation concerns due to negative earnings also impact the score.

Positive Factors

Strong Gross Margin

A high gross margin indicates efficient cost management and strong pricing power, which can support profitability as the company scales.

No Debt

Having no debt reduces financial risk and provides flexibility to invest in growth opportunities without the burden of interest payments.

Management Restructuring

Experienced leadership can drive strategic initiatives and operational efficiency, supporting long-term growth and stability.

Negative Factors

Declining Revenue

A decline in revenue suggests challenges in market penetration or product adoption, which could impact future growth prospects.

Consistent Net Losses

Ongoing net losses highlight profitability challenges, potentially limiting reinvestment in R&D and market expansion.

Negative Free Cash Flow

Persistent negative cash flow indicates challenges in generating sufficient cash from operations, impacting financial sustainability.

Sight Sciences Business Overview & Revenue Model

Company Description

Sight Sciences, Inc., an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. The company's products include OMNI Surgical System, a therapeutic device used by ophthalmic surgeons to reduce intraocular pressure in adult glaucoma patients; and TearCare System, a wearable eyelid technology for the treatment of dry eye disease (DED) for ophthalmologists and optometrists. It offers its products through sales representatives and distributors to hospitals, medical centers, and eyecare professionals in the United States. The company was incorporated in 2010 and is headquartered in Menlo Park, California.

How the Company Makes Money

Sight Sciences generates revenue primarily through the sale of its medical devices and surgical systems to hospitals, outpatient surgical centers, and eye care professionals. The company's key revenue streams include direct sales of its OMNI Surgical System and related consumable products, which are used in glaucoma surgeries. Additionally, Sight Sciences may benefit from strategic partnerships with healthcare providers and distributors, which can enhance its market reach and facilitate the adoption of its technologies. Ongoing investments in research and development also position the company to introduce new products and expand its offerings, contributing to long-term revenue growth.

Sight Sciences Financial Statement Overview

Summary

Sight Sciences shows a strong gross margin and liquidity position with no debt, which are positive indicators. However, challenges include declining revenues, consistent net losses, and negative free cash flow. The reduction in equity suggests potential sustainability concerns if these trends continue.

Income Statement

Sight Sciences shows a declining revenue trend with a revenue decrease from $81.1M in 2023 to $79.9M in 2024, marking a negative revenue growth rate of -1.47%. The company is also operating at a loss, with a net profit margin of -64.5% in 2024, which is a slight improvement from -68.5% in 2023. The gross profit margin is relatively high at 85.5% in 2024, indicating efficient cost management concerning direct costs, but there is a consistent negative EBIT and EBITDA margin due to high operating expenses.

Balance Sheet

The balance sheet reflects a strong liquidity position with a significant amount of cash and cash equivalents ($120.4M) and no debt as of 2024, resulting in a net negative debt position. The equity ratio stands at 61.3%, indicating a solid equity foundation. However, the company has been experiencing a decrease in stockholders' equity from $120.2M in 2023 to $87.5M in 2024. The absence of debt reduces financial risk, but declining equity could be a concern.

Cash Flow

Free cash flow remains negative at -$22.7M in 2024, though there is an improvement from -$47.9M in 2023. The operating cash flow to net income ratio is close to 0.43, reflecting some alignment between operational cash generation and reported losses. Despite improvement, persistent negative cash flows highlight ongoing challenges in generating sufficient cash from operations.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	76.05M	79.87M	81.06M	71.33M	48.96M	27.64M
Gross Profit	65.44M	68.28M	69.17M	58.97M	40.35M	18.43M
EBITDA	-42.73M	-45.90M	-49.41M	-80.48M	-57.20M	-31.68M
Net Income	-46.11M	-51.51M	-55.55M	-86.24M	-62.96M	-34.69M
Balance Sheet
Total Assets	116.26M	142.84M	166.65M	213.07M	280.19M	72.81M
Cash, Cash Equivalents and Short-Term Investments	92.37M	120.36M	138.13M	185.00M	260.69M	61.51M
Total Debt	0.00	40.36M	35.41M	34.98M	34.21M	32.48M
Total Liabilities	51.97M	55.32M	46.44M	53.00M	48.08M	161.66M
Stockholders Equity	64.29M	87.52M	120.22M	160.08M	232.11M	-88.85M
Cash Flow
Free Cash Flow	-31.84M	-22.74M	-47.98M	-76.94M	-53.35M	-33.13M
Operating Cash Flow	-31.33M	-22.35M	-47.18M	-75.97M	-52.54M	-32.17M
Investing Cash Flow	-517.00K	-385.00K	-791.00K	-970.00K	-813.00K	-953.00K
Financing Cash Flow	5.92M	4.96M	1.10M	1.25M	252.53M	73.40M

Sight Sciences Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 5.82
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SGHT, the sentiment is Positive. The current price of 5.82 is above the 20-day moving average (MA) of 4.76, above the 50-day MA of 4.02, and above the 200-day MA of 3.46, indicating a bullish trend. The MACD of 0.41 indicates Negative momentum. The RSI at 77.96 is Negative, neither overbought nor oversold. The STOCH value of 55.70 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for SGHT.

Sight Sciences Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
FONR	64 Neutral	$93.07M	12.04	4.92%	―	1.43%	-20.12%
SGHT	58 Neutral	$260.79M	-5.19	-57.10%	―	-3.89%	9.68%
CVRX	55 Neutral	$256.03M	―	-91.88%	―	18.44%	25.42%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
TLSI	47 Neutral	$218.92M	―	―	―	45.50%	53.07%
RCEL	42 Neutral	$90.50M	―	-935.73%	―	38.32%	-1.31%
LNSR	38 Underperform	$145.13M	―	-422.35%	―	21.02%	-200.88%

Sight Sciences Corporate Events

Sight Sciences Raises Revenue Guidance Amid Strategic Shifts

Sight Sciences, Inc. is an eyecare technology company that develops and commercializes innovative interventional technologies aimed at transforming patient care in the ophthalmology sector. The company is known for its minimally invasive solutions targeting prevalent eye diseases such as glaucoma and dry eye disease.

Sight Sciences Announces Key Management Changes

Sight Sciences announced significant management changes effective November 5, 2025, with Alison Bauerlein promoted to Chief Operating Officer and James Rodberg appointed as Chief Financial Officer. The company also reported its third-quarter 2025 financial results, showing a slight revenue decline of 1% compared to the previous year, with a notable 6% increase in surgical glaucoma revenue. Despite a decrease in dry eye revenue, the company raised its full-year 2025 revenue guidance and reduced its adjusted operating expense guidance, reflecting strong operational execution and market positioning. The company’s strategic focus on achieving reimbursed market access for its TearCare procedure and expanded coverage for its OMNI Surgical System reflects its commitment to long-term growth and stakeholder value.

The most recent analyst rating on (SGHT) stock is a Buy with a $5.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Sight Sciences’ Latest Study on OMNI 3.0 System: A Potential Game-Changer for Glaucoma Treatment

Study Overview: Sight Sciences, Inc. is conducting a pilot study titled A Pilot Study of the OMNI 3.1 Surgical System in Subjects With Primary Open-Angle Glaucoma. The study aims to gather early evidence on the safety and effectiveness of the OMNI 3.0 Surgical System in lowering intraocular pressure in patients with primary open-angle glaucoma (POAG), a significant condition affecting eye health.

Sight Sciences’ Helix Surgical System Study: A Potential Game-Changer for Glaucoma and Cataract Treatment

Study Overview: Sight Sciences, Inc. is conducting a pilot study titled ‘A Pilot Study of the Helix Surgical System in Subjects With Primary Open-Angle Glaucoma (POAG) and Cataract.’ The study aims to evaluate the safety of the Helix Surgical System during cataract surgery and gather preliminary evidence of its effectiveness in reducing intraocular pressure in patients with mild to moderate POAG and cataracts.

Sight Sciences Gains Medicare Pricing for TearCare

On October 17, 2025, Sight Sciences announced that Novitas Solutions and First Coast Service Options established jurisdiction-wide pricing for the TearCare System procedure under CPT code 0563T, effective January 1, 2025. This development, covering 10.4 million Medicare beneficiaries, is expected to enhance patient access to the TearCare procedure, supporting the company’s engagement with third-party payors and clinical societies.

The most recent analyst rating on (SGHT) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Sight Sciences Amends Loan Agreement with Hercules

On September 30, 2025, Sight Sciences, Inc. amended its Loan and Security Agreement with Hercules Capital, Inc., extending the interest-only period to February 1, 2027. The amendment reallocates a $10 million tranche, increasing the available amount to $25 million during the interest-only period, subject to Hercules’ approval, while maintaining the overall $65 million credit facility, impacting the company’s financial flexibility and potential growth.

The most recent analyst rating on (SGHT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Sight Sciences Announces Workforce Reduction Plan

On August 27, 2025, Sight Sciences, Inc. announced a targeted plan to reduce operating expenses and improve cost efficiencies by reducing its workforce by 20% and delaying certain R&D projects. The plan aims to align the company’s operations for long-term growth without additional equity capital, with expected annual savings of approximately $11.9 million. The company also announced the departure of Chief Commercial Officer Matthew Link, effective August 31, 2025, with no immediate plans to fill the position. Despite these changes, Sight Sciences reaffirmed its revenue guidance for 2025 and expects a mid-single-digit decline in third-quarter surgical glaucoma revenue compared to the previous year.

The most recent analyst rating on (SGHT) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.

Sight Sciences’ Earnings Call: Balancing Growth and Challenges

Sight Sciences, Inc. recently held its earnings call, revealing a balanced sentiment of optimism and caution. The company showcased strong operational performance and an upward revision in revenue guidance, primarily driven by the success of its Surgical Glaucoma segment and new product launches. However, challenges such as reimbursement hurdles for TearCare and tariff-related cost impacts remain significant concerns.

Sight Sciences Reports Q2 2025 Financial Results

Sight Sciences, Inc. is an eyecare technology company that develops and commercializes innovative interventional technologies aimed at transforming care and improving patients’ lives, focusing on minimally invasive solutions for glaucoma and dry eye disease.

Sight Sciences Raises Full-Year Revenue Guidance

On August 7, 2025, Sight Sciences reported its financial results for the second quarter of 2025, showing a total revenue of $19.6 million, an 8% decrease from the previous year, primarily due to reduced revenue from its Surgical Glaucoma segment. Despite the decline, the company raised its full-year revenue guidance, reflecting confidence in its market position and ongoing efforts to enhance patient outcomes through innovative technologies.

The most recent analyst rating on (SGHT) stock is a Hold with a $4.00 price target. To see the full list of analyst forecasts on Sight Sciences stock, see the SGHT Stock Forecast page.